浙江医药股份有限公司 2025 年限制性股票激励计划 （草案） 浙江医药股份有限公司 证券简称：浙江医药 证券代码：600216 二〇二五年十月 本公司所有激励对象承诺，公司因信息披露文件中有虚假记载、误导性陈述 或者重大遗漏，导致不符合授予权益或行使权益安排的，激励对象应当自相关信 息披露文件被确认存在虚假记载、误导性陈述或者重大遗漏后，将由本激励计划 所获得的全部利益返还公司。 -I- 浙江医药股份有限公司 2025 年限制性股票激励计划（草案） 特别提示 一、本激励计划依据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司股权激励管理办法》及其他有关法律、法规、规章和规范性文件，以 及《浙江医药股份有限公司章程》制订。 二、本激励计划采取的激励工具为限制性股票。股票来源为公司从二级市场 回购的本公司人民币 A 股普通股股票。 三、本激励计划拟向激励对象授予合计不超过 1,028.4000 万股公司限制性股 票，约占本激励计划草案公告时公司股本总额 96,163.7750 万股的 1.0694%，不 设置预留权益。 浙江医药股份有限公司 2025 年限制性股票激励计划（草案） 声 明 本公司董事 ...

国浩律师（上海）事务所 关 于 浙江医药股份有限公司 2025 年限制性股票激励计划（草案） 之 法 律 意 见 书 上海市静安区山西北路 99 号苏河湾中心 25-28 层 邮编：200085 25-28th Floor, Suhe Centre, No.99 North Shanxi Road, Shanghai 200085, China 电话/Tel： +86 21 5234 1668 传真/Fax： +86 21 5243 3320 网址/Website： http：//www.grandall.com.cn 二〇二五年十月 | 义 释 2 | | | --- | --- | | 第一节 律师声明事项 5 | | | 第二节 正文 6 | | | 一、公司实施本次激励计划的主体资格 | 6 | | 二、本次激励计划的主要内容及合法合规性 | 7 | | 三、实施本次激励计划所需履行的主要程序 | 8 | | 四、本次激励计划激励对象的确定 | 10 | | 五、本次股权激励计划的信息披露 | 10 | | 六、公司未就本次激励计划向激励对象提供财务资助 | 11 | | 七、本次激励计划对公司及全体 ...

Core Viewpoint - Zhejiang Medicine announced an incentive plan involving 875 participants, granting up to 10.284 million restricted stocks, representing approximately 1.0694% of the company's total share capital of about 962 million shares [1] Group 1: Incentive Plan Details - The incentive plan will grant restricted stocks at a price of 7.3 yuan per share, with a maximum validity of 36 months from the completion of the stock registration [1] - The stocks are sourced from the company's repurchased A-shares in the secondary market, with no reserved rights set [1] Group 2: Financial Performance - For the first half of 2025, Zhejiang Medicine's revenue composition is as follows: pharmaceuticals account for 51.44%, human nutritional products for 47.06%, and other businesses for 1.51% [1] - As of the report date, Zhejiang Medicine's market capitalization stands at 13.9 billion yuan [1]

Core Viewpoint - Zhejiang Medicine announced a board meeting to discuss the 2025 restricted stock incentive plan, indicating a strategic move to enhance employee motivation and align interests with shareholders [1] Financial Performance - For the first half of 2025, Zhejiang Medicine's revenue composition was as follows: pharmaceuticals accounted for 51.44%, human nutritional products for 47.06%, other products for 0.85%, and other business activities for 0.66% [1] Market Position - As of the report, Zhejiang Medicine's market capitalization stood at 13.9 billion yuan [1]

Core Viewpoint - The company aims to enhance its self-sufficiency in raw materials for vitamins and reduce reliance on external intermediates through a significant investment project [1] Investment Project Summary - Zhejiang Changbei Biological Co., Ltd., a subsidiary of the company, plans to invest approximately 168.5 million yuan in the construction of a project to produce vitamin intermediates [1] - The project is expected to generate annual sales of 900 million yuan and a gross profit of 286 million yuan upon completion [1] - This investment decision aligns with the company's strategic development and business layout, although future operational effectiveness carries some uncertainty [1]

一、主要财务数据 浙江医药股份有限公司2025 年第三季度报告 证券代码：600216 证券简称：浙江医药 浙江医药股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 比上年同 | 年初至报告期末 | 末比上年同期 | | | | 期增减变 | | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 2,372,423,164.56 | -12.37 | 6,695,297, ...

浙江医药股份有限公司 2025 年限制性股票激励计划实施考核管理办法 浙江医药股份有限公司（以下简称"公司"）为了进一步完善公司治理结 构，健全公司长效激励机制，促进公司董事、高级管理人员以及核心骨干员工勤 奋努力工作，实现股东、公司和激励对象利益的一致，确保公司长远发展与股东 利益的最大化，公司计划实施2025年限制性股票激励计划（以下简称"本激励计 划"）。为保证本激励计划在经批准后顺利实施，现根据《中华人民共和国公司 法》《中华人民共和国证券法》《上市公司股权激励管理办法》等有关法律、法 规及《浙江医药股份有限公司章程》的规定，结合公司实际情况，制定本办法。 一、总则 （一）考核目的 制定本办法的目的是加强本激励计划执行的计划性，量化本激励计划设定 的具体目标，促进激励对象考核管理的科学化、规范化、制度化，实现本激励计 划的各项业绩指标；同时引导激励对象提高工作绩效，提升工作能力，客观、公 正评价员工的绩效和贡献，为本激励计划的执行提供客观、全面的评价依据。 （二）考核原则 考核评价必须坚持公正、公开、公平的原则，严格按照本办法对考核对象 的工作业绩、能力、态度进行评价，考核评价做到定量与定性考核相结合 ...

Core Viewpoint - Zhejiang Medicine (600216.SH) announced an investment of 1.685 billion yuan in its subsidiary Changbei Biological to enhance the self-sufficiency of raw materials for vitamins and reduce reliance on external intermediates [1] Investment Details - The project will be constructed in two phases [1] - Upon completion, the project is expected to generate annual sales of 900 million yuan and a gross profit of 286 million yuan [1] Strategic Rationale - The investment decision is based on the company's development strategy and business layout [1] - There is a noted uncertainty regarding the future operational effectiveness of the project [1]

Core Viewpoint - Zhejiang Medicine (600216.SH) announced that its subsidiary Changbei Biological plans to invest 1.685 billion yuan in the construction of the Zhejiang Medicine Changbei Biological Project, aimed at enhancing the self-sufficiency of raw materials for vitamins and reducing dependence on external key intermediates [1] Investment Details - The project will be constructed in two phases [1] - Upon completion, the project is expected to achieve an annual sales revenue of 900 million yuan and a gross profit of 286 million yuan [1] Strategic Rationale - The investment decision is based on the company's development strategy and business layout [1] - There is a noted uncertainty regarding the realization of future operational benefits from this investment [1]

Core Viewpoint - Zhejiang Medicine's stock price has shown a decline of 7.58% year-to-date, with a recent increase of 2.07% on September 24, 2023, indicating potential volatility in the market [1]. Financial Performance - For the first half of 2025, Zhejiang Medicine reported a revenue of 4.323 billion yuan, a year-on-year decrease of 1.87%, while the net profit attributable to shareholders was 673 million yuan, reflecting a significant increase of 113.52% [2]. - Cumulative cash dividends since the company's A-share listing amount to 4.377 billion yuan, with 661 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 65,500, with an average of 14,674 circulating shares per person, a decrease of 0.55% [2]. - The top circulating shareholder, Hong Kong Central Clearing Limited, holds 71.2904 million shares, an increase of 34.9417 million shares compared to the previous period [3].